Anna Walentinsson

This paper develops human mini-heart models of HFpEF, identifies SERCA2a downregulation, and demonstrates gene therapy efficacy, leading to a first-in-human clinical trial.

The paper shows that IDH2, a mitochondrial enzyme, acts as a major antioxidant defense in cardiomyocytes, with its activity compensating for reduced expression in heart failure, and identifies an epigenetic mechanism linking oxidative stress to cardiac function.

This study identifies seven genes associated with heart failure progression using exome sequencing in 8,089 patients and prioritizes them for therapeutic target validation.

The paper identifies three genes associated with heart failure using human exome sequencing and validates their roles in cardiovascular function using zebrafish CRISPR/Cas9 mutagenesis.